Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KATHRYN S MOFFETT

Allopathic & Osteopathic Physicians Pediatrics Pediatric Infectious Diseases

NPI
1023132750
CMS profile
273107
Location
MORGANTOWN, WV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$122.10

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $122.10 1

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Vertex Pharmaceuticals Incorporated $122.10 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KATHRYN S MOFFETT

NPI 1023132750 · CMS profile ID 273107

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Infectious Diseases

MORGANTOWN, WV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1023132750?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KATHRYN S MOFFETT, NPI 1023132750, CMS profile ID 273107. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023132750?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). KATHRYN S MOFFETT, NPI 1023132750, CMS profile ID 273107. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023132750?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
KATHRYN S MOFFETT, NPI 1023132750, CMS profile ID 273107, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1023132750?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $122.10 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Vertex Pharmaceuticals Incorporated $122.1011/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899691909 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,406.97 15
PY2020 $6,132.82 15
PY2021 $33.95 1
PY2022 $122.10 1
PY2025 $17.50 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $32,650.14 2
PY2024 Principal investigator $69,780.52 3
PY2023 Principal investigator $68,365.82 5
PY2022 Principal investigator $77,924.85 6
PY2021 Principal investigator $37,326.44 11
PY2020 Principal investigator $81,879.44 29
PY2019 Principal investigator $114,244.75 47

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

47 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $16.80 12/09/2019 Non-covered Recipient Entity
West Virginia University
A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection No dispute reported 06/30/2026 691536233
Principal investigator 1 Merck Sharp & Dohme Corporation $29.70 12/09/2019 Non-covered Recipient Entity
West Virginia University
A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection No dispute reported 06/30/2026 691539161
Principal investigator 1 Merck Sharp & Dohme Corporation $1.56 12/09/2019 Non-covered Recipient Entity
West Virginia University
A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection No dispute reported 06/30/2026 691539499
Principal investigator 1 Merck Sharp & Dohme Corporation $13.20 12/09/2019 Non-covered Recipient Entity
West Virginia University
A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection No dispute reported 06/30/2026 691539667
Principal investigator 1 Merck Sharp & Dohme Corporation $2.00 12/09/2019 Non-covered Recipient Entity
West Virginia University
A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection No dispute reported 06/30/2026 691539669
Principal investigator 1 Merck Sharp & Dohme Corporation $20.26 12/09/2019 Non-covered Recipient Entity
West Virginia University
A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection No dispute reported 06/30/2026 691539671
Principal investigator 1 Merck Sharp & Dohme Corporation $29.70 12/09/2019 Non-covered Recipient Entity
West Virginia University
A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection No dispute reported 06/30/2026 691539673
Principal investigator 1 Merck Sharp & Dohme Corporation $35.16 12/09/2019 Non-covered Recipient Entity
West Virginia University
A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection No dispute reported 06/30/2026 691539913
Principal investigator 1 Merck Sharp & Dohme Corporation $9.12 12/09/2019 Non-covered Recipient Entity
West Virginia University
A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection No dispute reported 06/30/2026 691540081
Principal investigator 1 Merck Sharp & Dohme Corporation $29.70 12/09/2019 Non-covered Recipient Entity
West Virginia University
A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection No dispute reported 06/30/2026 691540205
Principal investigator 1 Merck Sharp & Dohme Corporation $3.42 12/09/2019 Non-covered Recipient Entity
West Virginia University
A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection No dispute reported 06/30/2026 691540207
Principal investigator 1 Merck Sharp & Dohme Corporation $3.80 12/09/2019 Non-covered Recipient Entity
West Virginia University
A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection No dispute reported 06/30/2026 691540211
Principal investigator 1 Merck Sharp & Dohme Corporation $30.92 12/09/2019 Non-covered Recipient Entity
West Virginia University
A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection No dispute reported 06/30/2026 691540213
Principal investigator 1 Merck Sharp & Dohme Corporation $6.12 12/09/2019 Non-covered Recipient Entity
West Virginia University
A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection No dispute reported 06/30/2026 691541389
Principal investigator 1 Merck Sharp & Dohme Corporation $70.45 12/09/2019 Non-covered Recipient Entity
West Virginia University
A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection No dispute reported 06/30/2026 691541391
Principal investigator 1 Merck Sharp & Dohme Corporation $8.40 12/09/2019 Non-covered Recipient Entity
West Virginia University
A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection No dispute reported 06/30/2026 691541393
Principal investigator 1 Tetraphase Pharmaceuticals, Inc. $3,593.65 11/12/2019 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY
A Safety and PK Study of IV Eravacycline No dispute reported 06/30/2026 708236001
Principal investigator 1 Tetraphase Pharmaceuticals, Inc. $7,187.29 10/29/2019 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY
A Safety and PK Study of IV Eravacycline No dispute reported 06/30/2026 708235999
Principal investigator 1 Gilead Sciences, Inc. $499.00 10/23/2019 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY RESEARCH CORP
A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Infection Trials No dispute reported 06/30/2026 676400781
Principal investigator 1 Merck Sharp & Dohme Corporation $10,500.00 10/23/2019 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY
A Phase 1, open-label, non-comparative, multicenter clinical trial to evaluate the safety, tolerability, and pharmacokinetics of ceftolozane,tazobactam MK-7625A in pediatric participants with nosocomial pneumonia No dispute reported 06/30/2026 691477523
Principal investigator 1 Tetraphase Pharmaceuticals, Inc. $3,000.00 10/22/2019 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY
A Safety and PK Study of IV Eravacycline No dispute reported 06/30/2026 708235997
Principal investigator 1 Merck Sharp & Dohme Corporation $1.26 10/09/2019 Non-covered Recipient Entity
West Virginia University
A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection No dispute reported 06/30/2026 691372323
Principal investigator 1 Merck Sharp & Dohme Corporation $1.26 10/09/2019 Non-covered Recipient Entity
West Virginia University
A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection No dispute reported 06/30/2026 691508793
Principal investigator 1 Merck Sharp & Dohme Corporation $64.80 09/30/2019 Covered Recipient Teaching Hospital
WEST VIRGINIA UNIVERSITY HOSPITALS
A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection No dispute reported 06/30/2026 713254841
Principal investigator 1 Merck Sharp & Dohme Corporation $1,154.40 09/11/2019 Non-covered Recipient Entity
West Virginia University
A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection No dispute reported 06/30/2026 691362991
Principal investigator 1 Janssen Research & Development, LLC $7,500.00 08/19/2019 Non-covered Recipient Entity
STATE OF WEST VIRGINIA WEST VIRGINI A UNIVERSITY
A Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Relationships of Different Doses of JNJ-53718678 in Children 28 Days and 3 Years of Age With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus Infection No dispute reported 06/30/2026 654258661
Principal investigator 1 Gilead Sciences, Inc. $1,809.00 07/10/2019 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY RESEARCH CORP
A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide in Children Adolescents with Chronic Hepatitis B Infection No dispute reported 06/30/2026 676400777
Principal investigator 1 Gilead Sciences, Inc. $1,000.00 07/08/2019 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY RESEARCH CORP
A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination in Adolescents and Children with Chronic HCV-Infection No dispute reported 06/30/2026 676400771
Principal investigator 1 AbbVie, Inc. $204.98 06/27/2019 Non-covered Recipient Entity
West Virginia University Research
P12-792 No dispute reported 06/30/2026 647565871
Principal investigator 1 Allergan Inc. $436.13 06/27/2019 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY RESEARCH CORPORATION
LONG-TERM STUDY IN US CYSTIC FIBROSIS PATIENTS RECEIVING DIGESTIVE ENZYME SUPPLEMENTS TO ASSESS ANY NARROWING OF THE LARGE INTESTINES CAUSING ADVERSE INTESTINAL SYMPTOMS FIBROSING COLONOPATHY No dispute reported 06/30/2026 670054053
Principal investigator 1 Merck Sharp & Dohme Corporation $1,000.00 06/19/2019 Non-covered Recipient Entity
West Virginia University
A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection No dispute reported 06/30/2026 691359601
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 06/06/2019 Non-covered Recipient Entity
W Virginia Univ Rsrch Corp.
A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus No dispute reported 06/30/2026 654265085
Principal investigator 1 Tetraphase Pharmaceuticals, Inc. $10,000.00 05/01/2019 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY
A Safety and PK Study of IV Eravacycline No dispute reported 06/30/2026 708235995
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 04/18/2019 Non-covered Recipient Entity
W Virginia Univ Rsrch Corp.
A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus No dispute reported 06/30/2026 654265083
Principal investigator 1 Gilead Sciences, Inc. $500.00 04/15/2019 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY RESEARCH CORP
A Phase 2, Open-Label, Multicenter, Multi-cohort, Single-Arm Study to Investigate the Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children with GT-2 or GT-3 Chronic HCV Infection No dispute reported 06/30/2026 676400761
Principal investigator 1 Gilead Sciences, Inc. $1,000.00 04/15/2019 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY RESEARCH CORP
A Phase 2, Open-Label, Multicenter, Multi-cohort, Single-Arm Study to Investigate the Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children with GT-2 or GT-3 Chronic HCV Infection No dispute reported 06/30/2026 676400767
Principal investigator 1 Merck Sharp & Dohme Corporation $7,500.00 04/12/2019 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE
A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection No dispute reported 06/30/2026 691322323
Principal investigator 1 Gilead Sciences, Inc. $762.00 04/03/2019 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY RESEARCH CORP
A Phase 2, Open-Label, Multicenter, Multi-cohort, Single-Arm Study to Investigate the Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children with GT-2 or GT-3 Chronic HCV Infection No dispute reported 06/30/2026 676400755
Principal investigator 1 Janssen Research & Development, LLC $1,700.00 03/14/2019 Non-covered Recipient Entity
W Virginia Univ Rsrch Corp.
A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus No dispute reported 06/30/2026 654265081
Principal investigator 1 Tetraphase Pharmaceuticals, Inc. $1,200.00 03/12/2019 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY
A Safety and PK Study of IV Eravacycline No dispute reported 06/30/2026 708235991
Principal investigator 1 Tetraphase Pharmaceuticals, Inc. $1,900.00 03/12/2019 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY
A Safety and PK Study of IV Eravacycline No dispute reported 06/30/2026 708235993
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $2,368.00 02/28/2019 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY HOSPITALS
A Post-approval Observational Study to Evaluate the Long-term Effectiveness and Safety of Orkambi in US Patients Who Completed Study VX12-809-105 Part A No dispute reported 06/30/2026 686139645
Principal investigator 1 AbbVie, Inc. $469.02 02/14/2019 Non-covered Recipient Entity
West Virginia University Research
P12-792 No dispute reported 06/30/2026 647565869
Principal investigator 1 Allergan Inc. $498.96 02/14/2019 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY RESEARCH CORPORATION
LONG-TERM STUDY IN US CYSTIC FIBROSIS PATIENTS RECEIVING DIGESTIVE ENZYME SUPPLEMENTS TO ASSESS ANY NARROWING OF THE LARGE INTESTINES CAUSING ADVERSE INTESTINAL SYMPTOMS FIBROSING COLONOPATHY No dispute reported 06/30/2026 670024797
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $27,462.84 01/01/2019 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY HOSPITALS
A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy No dispute reported 06/30/2026 686139641
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $7,598.56 01/01/2019 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY HOSPITALS
A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F) No dispute reported 06/30/2026 686139643
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $11,023.29 01/01/2019 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY HOSPITALS
A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF) No dispute reported 06/30/2026 686139647